The study aimed to identify predictive factors for early recurrence and survival outcomes in colorectal cancer patients with liver and peritoneal metastases who underwent combined liver resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. The results showed that patients with advanced primary tumors (PT4 and/or PN2 status) had a higher risk of early recurrence, while retroperitoneal […]
Category: Cytoreductive Surgery & Peritoneum
Textbook Oncologic Outcomes Enhance Survival in CRS and HIPEC for Colorectal Peritoneal Metastasis
Expert consensus was achieved on the definition of textbook oncologic outcomes (TOO) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastasis. The consensus criteria included the absence of unplanned re-operations, severe postoperative complications, unplanned readmissions, 90-day postoperative mortality, and contraindications for chemotherapy within 12 weeks. In a cohort of 251 patients, […]
Preoperative 18F-FDG PET/CT Associated with Pathological Tumor Grade in Pseudomyxoma Peritonei
The clinical effectiveness of preoperative 18F-FDG PET/CT in predicting pathological tumor grade in patients with pseudomyxoma peritonei (PMP) originating from the appendix was evaluated in this retrospective cohort study. The study found that high-grade PMP patients had a significantly higher median standardized uptake value (SUVmax) on 18F-FDG PET/CT compared to low-grade patients. The highest area […]
Extent of Surgery Found to Impact Gastrointestinal Function in Patients Undergoing CRS and HIPEC
This study investigated the impact of the extent of surgery on late adverse effects (LAEs) in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The study found that patients undergoing extensive CRS experienced persistent impaired gastrointestinal function in terms of diarrhea, compared to those undergoing less extensive surgery. However, the levels of other […]
Financial toxicity risk among patients undergoing CRS-HIPEC: Study reveals one-third at risk
Researchers conducted a retrospective cohort study on 163 patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) between 2016 and 2022. They found that 31.9% of patients were at risk of financial toxicity, with higher out-of-pocket expenditures and lower income quartiles being significant risk factors. The median out-of-pocket expenditure for at-risk patients was $5000, […]
Long-term Survival in Patients with Colorectal Peritoneal Carcinomatosis Treated with CRS/HIPEC
Actual 5-year survival rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for patients with peritoneal carcinomatosis (PC) of colorectal origin were reported in this study. A total of 103 patients were analyzed, with a median follow-up of survivors at 88 months. The 5-year overall survival (OS) was 36%, and the median OS was 42.5 […]
Equivalency in Colorectal Metastases Management: Liver vs. Peritoneum
Examining outcomes in metastatic colorectal cancer treatment, researchers conducted a review, analyzing six selected studies. Comparing surgical interventions on the liver and peritoneum, cytoreductive surgery with heated intraperitoneal chemotherapy showed comparable safety and survival outcomes to hepatectomy. This suggests a need for early integration of cytoreduction in the management algorithm for colorectal cancer patients with […]
Distance and Disparities in Cytoreductive Surgery
Analyzing 1614 cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) cases, researchers found that over 50% of patients traveled more than 100 miles for treatment. While regionalization showed no survival difference, those traveling further had fewer disparities but higher disease severity, raising concerns about access for the underserved, time to treatment, and surgical quality. Median […]
HIPEC Consensus: Dutch Protocol Prevails for Colorectal Cancer Peritoneal Metastases
Global Experts Agree: In treating colorectal cancer with peritoneal metastases, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) extends median overall survival beyond 40 months. The consensus among 78% of international panelists highlights the conditionally recommended use of HIPEC post-surgery. The Dutch protocol, featuring mitomycin-C, gains preference over the short, high-dose oxaliplatin regimen. Despite weak evidence, […]
Intraperitoneal Paclitaxel Shows Promise: Effective and Tolerable Combo for Gastric Cancer with Peritoneal Metastasis
In a phase II study, researchers explored the efficacy of intraperitoneal paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Among 53 patients, the treatment achieved a 73.6% 1-year overall survival rate, meeting the primary endpoint. The median survival time was 19.4 months, and the 1-year progression-free survival rate reached 49.6%. While […]